96 weeks of pegylated-Interferon- alpha-2? plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study

Wedemeyer, HeinerYurdaydin, CihanErnst, StefanieCaruntu, Florin A.Curescu, Manuela G.Yalcin, KendalAkarca, Ulus S.2024-04-242024-04-2420130270-91391527-3350https://hdl.handle.net/11468/2313564th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases -- NOV 01-05, 2013 -- Washington, DC[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]96 weeks of pegylated-Interferon- alpha-2? plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study96 weeks of pegylated-Interferon- alpha-2? plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 studyConference Object58222A223AWOS:000330252201031Q1